The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.